§ 99.3 Definitions. ( a ) Agency or FDA means the Food and Drug Administration.
( b ) For purposes of this part, a *clinical investigation* is an investigation in humans that tests a specific clinical hypothesis.
( c ) *Group health plan* means an employee welfare benefit plan (as defined in section 3(1) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1002(1))) to the extent that the plan provides medical care (as defined in paragraphs (c)(1) through (c)(3) of this section and including items and services paid for as medical care) to employees or their dependents (as defined under the terms of the plan) directly or through insurance, reimbursement, or otherwise. For purposes of this part, the term *medical care* means: ( 1 ) Amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease, or amounts paid for the purpose of affecting any structure or function of the body;
( 2 ) Amounts paid for transportation primarily for and essential to medical care referred to in paragraph (c)(1) of this section; and
( 3 ) Amounts paid for insurance covering medical care referred to in paragraphs (c)(1) and (c)(2) of this section.
( d ) *Health care practitioner* means a physician or other individual who is a health care provider and licensed under State law to prescribe drugs or devices.
( e ) *Health insurance issuer* means an insurance company, insurance service, or insurance organization (including a health maintenance organization, as defined in paragraph (e)(2) of this section) which is licensed to engage in the business of insurance in a State and which is subject to State law which regulates insurance (within the meaning of section 514(b)(2) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1144(b)(2))). ( 1 ) Such term does not include a group health plan.
( 2 ) For purposes of this part, the term *health maintenance organization* means: ( i ) A Federally qualified health maintenance organization (as defined in section 1301(a) of the Public Health Service Act (42 U.S.C. 300e(a)));
( ii ) An organization recognized under State law as a health maintenance organization; or
( iii ) A similar organization regulated under State law for solvency in the same manner and to the same extent as such a health maintenance organization.
( f ) *Manufacturer* means a person who manufactures a drug or device or who is licensed by such person to distribute or market the drug or device. For purposes of this part, the term may also include the sponsor of the approved, licensed, or cleared drug or device.
( g ) *New use* means a use that is not included in the approved labeling of an approved drug or device, or a use that is not included in the statement of intended use for a cleared device.
( h ) *Pharmacy benefit manager* means a person or entity that has, as its principal focus, the implementation of one or more device and/or prescription drug benefit programs.
( i ) A *reference publication* is a publication that: ( 1 ) Has not been written, edited, excerpted, or published specifically for, or at the request of, a drug or device manufacturer;
( 2 ) Has not been edited or significantly influenced by such a manufacturer;
( 3 ) Is not solely distributed through such a manufacturer, but is generally available in bookstores or other distribution channels where medical textbooks are sold;
( 4 ) Does not focus on any particular drug or device of a manufacturer that disseminates information under this part and does not have a primary focus on new uses of drugs or devices that are marketed or are under investigation by a manufacturer supporting the dissemination of information; and
( 5 ) Does not present materials that are false or misleading.
( j ) *Scientific or medical journal* means a scientific or medical publication: ( 1 ) That is published by an organization that has an editorial board, that uses experts who have demonstrated expertise in the subject of an article under review by the organization and who are independent of the organization, to review and objectively select, reject, or provide comments about proposed articles, and that has a publicly stated policy, to which the organization adheres, of full disclosure of any conflict of interest or biases for all authors or contributors involved with the journal or organization;
( 2 ) Whose articles are peer-reviewed and published in accordance with the regular peer-review procedures of the organization;
( 3 ) That is generally recognized to be of national scope and reputation;
( 4 ) That is indexed in the Index Medicus of the National Library of Medicine of the National Institutes of Health; and
( 5 ) That is not in the form of a special supplement that has been funded in whole or in part by one or more manufacturers.
( k ) *Supplemental application* means: ( 1 ) For drugs, a supplement to support a new use to an approved new drug application;
( 2 ) For biologics, a supplement to an approved license application;
( 3 ) For devices that are the subject of a cleared 510(k) submission and devices that are exempt from the 510(k) process, a new 510(k) submission to support a new use or, for devices that are the subject of an approved premarket approval application, a supplement to support a new use to an approved premarket approval application.